ReviewExperimental biology and medicine (Maywood, N.J.)2019
Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?
Review in Experimental biology and medicine (Maywood, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07025980 (Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters in Patients With Metabolic Associated Steatotic Liver Disease), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters in Patients With Metabolic Associated Steatotic Liver Disease
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- High alcohol-producing Escherichia coli causes obesity and steatotic liver disease in a non-alcoholic cohort -a preclinical study.BMC microbiology · 2025Article
- The Gut Microbiome and Its Impact on Mood and Decision-Making: A Mechanistic and Therapeutic Review.Nutrients · 2025Review
- Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.World journal of gastroenterology · 2023Review
- Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease.Frontiers in cellular and infection microbiology · 2023Article
- The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Journal of clinical medicine · 2022Review
- Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease.Frontiers in pharmacology · 2022Review
- Review
- Gut microbiome profiles associated with steatosis severity in metabolic associated fatty liver disease.Hepatoma research · 2021Article
- Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives.Molecules (Basel, Switzerland) · 2020Review
- Intestinal Microecology: An Important Target for Chinese Medicine Treatment of Non-alcoholic Fatty Liver Disease.Chinese journal of integrative medicine · 2020Review
- Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease.Journal of clinical and translational hepatology · 2020Review
- Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.Journal of gastroenterology · 2020Review
- Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients.Frontiers in oncology · 2020Review
- Microbiome: Our opponents or allies in healthcare and medicine.Experimental biology and medicine (Maywood, N.J.) · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
impact statementThis invited minireview for the upcoming thematic issue on the microbiome addresses the role of the microbiome in nonalcoholic fatty liver disease (NAFLD). The incidence of NAFLD has increased greatly in recent years in parallel with the rise in obesity and is now believed to have a population prevalence of 20-40%. It is anticipated to soon become the primary cause of liver-related morbidity and mortality, and unfortunately, there are few treatment options. Therefore, there is a critical need for improved understanding of NAFLD pathophysiology to provide new avenues for therapeutic intervention. In this paper, we have reviewed evidence from human and animal model studies that have associated microbiome composition and microbial metabolites with development and progression of NAFLD. We have also discussed proposed mechanisms by which the microbiome could contribute to NAFLD pathogenesis and addressed future directions for this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.